TG and hypertriglyceridemia: Measures, including using, monitoring levels at baseline and during induction and intensification after receiving PEG‐asparaginase to safely receive treatment in subsequent cycles, anti‐TG medications and PEG‐asparaginase dose reductions in subsequent cycles, can help to reduce the incidence of hypertriglyceridemia and its associated complications, although this needs to be further confirmed in larger prospective studies.